BidaskClub downgraded shares of Inogen (NASDAQ:INGN) from a hold rating to a sell rating in a report issued on Saturday, January 6th.
A number of other equities analysts also recently issued reports on the stock. Zacks Investment Research raised shares of Inogen from a hold rating to a buy rating and set a $131.00 price objective on the stock in a report on Thursday, November 9th. Leerink Swann reaffirmed an outperform rating and set a $120.00 price objective (up from $115.00) on shares of Inogen in a report on Wednesday, November 8th. Needham & Company LLC lifted their price objective on shares of Inogen from $108.00 to $125.00 and gave the stock a strong-buy rating in a report on Wednesday, November 8th. Finally, Piper Jaffray Companies reaffirmed a hold rating and set a $90.00 price objective on shares of Inogen in a report on Tuesday, September 12th. Five equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of Buy and a consensus price target of $102.71.
Inogen (NASDAQ INGN) traded down $4.40 during midday trading on Friday, reaching $121.84. 96,598 shares of the company traded hands, compared to its average volume of 141,272. Inogen has a twelve month low of $63.24 and a twelve month high of $130.05. The firm has a market cap of $2,530.00, a P/E ratio of 85.20, a P/E/G ratio of 4.27 and a beta of 1.13.
Inogen (NASDAQ:INGN) last posted its quarterly earnings data on Tuesday, November 7th. The medical technology company reported $0.33 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.29 by $0.04. The firm had revenue of $69.00 million for the quarter, compared to the consensus estimate of $63.55 million. Inogen had a net margin of 11.36% and a return on equity of 13.37%. The business’s revenue for the quarter was up 26.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.25 EPS. analysts forecast that Inogen will post 1.19 EPS for the current fiscal year.
In related news, EVP Matt Scribner sold 2,500 shares of the business’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $116.17, for a total value of $290,425.00. Following the sale, the executive vice president now directly owns 7,297 shares in the company, valued at approximately $847,692.49. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Scott Wilkinson sold 30,651 shares of the business’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $115.75, for a total value of $3,547,853.25. Following the completion of the sale, the insider now owns 38,107 shares in the company, valued at $4,410,885.25. The disclosure for this sale can be found here. Insiders have sold a total of 113,651 shares of company stock worth $13,299,463 over the last quarter. Company insiders own 5.31% of the company’s stock.
Institutional investors have recently made changes to their positions in the stock. Lenox Wealth Advisors Inc. bought a new stake in Inogen in the 4th quarter valued at about $100,000. Steward Partners Investment Advisory LLC raised its stake in Inogen by 1,000.0% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 1,100 shares of the medical technology company’s stock valued at $130,000 after acquiring an additional 1,000 shares during the period. Schroder Investment Management Group bought a new stake in Inogen in the 2nd quarter valued at about $132,000. Ameritas Investment Partners Inc. raised its stake in Inogen by 6.1% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 1,495 shares of the medical technology company’s stock valued at $143,000 after acquiring an additional 86 shares during the period. Finally, Sei Investments Co. raised its stake in Inogen by 38.1% in the 2nd quarter. Sei Investments Co. now owns 1,606 shares of the medical technology company’s stock valued at $153,000 after acquiring an additional 443 shares during the period.
ILLEGAL ACTIVITY WARNING: “BidaskClub Lowers Inogen (INGN) to Sell” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/01/31/inogen-ingn-cut-to-sell-at-bidaskclub.html.
Inogen Company Profile
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.